Human RCT
Mensch
Colao A, et al. (Pasireotide B2305 Study Group) 2012
In a phase 3 trial, lowers cortisol (urinary free cortisol) in Cushing's disease.
What does NOT follow: Approved indication; use in healthy people is not intended.
Peptide entry · Research other
Pasireotid
Pasireotide · Signifor · Signifor LAR
Highest evidence
Human RCT
Studies recorded
1· 1 in humans
Legal status · US
PrescriptionScientific context only. Not medical advice, not a recommendation to use.
At a glance
Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly.
Researched for
Cushing's diseaseAcromegalyACTH/GH suppression
Official status
US: Prescription
FDA-approved (Cushing's 2012, acromegaly LAR 2014).
At a glance
Overview
What is it?
Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly.
How is it meant to work? →
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
What do studies show? →
Human RCTIn a phase 3 trial, lowers cortisol (urinary free cortisol) in Cushing's disease.
What do users report?
No documented community reports.
01
Mechanism of action
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
03
What the studies show
Human RCT
Mensch
Lowers GH/IGF-1 in acromegaly (LAR form).
What does NOT follow: Also effective in a subset of patients inadequately controlled by older analogs.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Hyperglycemia / new-onset diabetes
More pronounced than with older somatostatin analogs, mediated via SSTR5 — a documented effect requiring monitoring.
sehr häufig
Human trial
Gallstones, gastrointestinal complaints
A class effect of somatostatin analogs.
häufig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
11
Legal status by country
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
- 1Enter the vial's substance amount (printed on the label).
- 2Enter how much solvent you add.
- 3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
Cofactors
These cofactors relate to the peptide class, not to a specific use. No recommendation, no dosing.
14
Study register
Human RCTRandomised controlled trial
Colao A, et al. (Pasireotide B2305 Study Group) · 2012
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
SamplePatients with Cushing's disease.
EndpointNormalization of urinary free cortisol.
Concrete results
Urinary free cortisol normalisation
26,3%
900 µg 2×/Tag, Monat 6 · 12 Monate
Findings:Pasireotide lowered urinary free cortisol in a relevant proportion of patients; hyperglycemia was a frequent issue.
Limitations:Hyperglycemia/diabetes as a class-limiting effect (SSTR5-mediated).
15
Sources & method
Last reviewed
2026-06-11
Get new studies on Pasireotid
Science only, no sales. Unsubscribe anytime.
We store your email only for the newsletter. Unsubscribe anytime. Privacy